Acute Respiratory Distress Syndrome (ARDS) Clinical Trial
— DACAPOOfficial title:
Influence of Quality of Care and Individual Patient Characteristics on Quality of Life/ Return to Work in Survivors of the Acute Respiratory Distress Syndrome (ARDS): Prospective, Observational, Multi-centre Cohort Study
The purpose of the DACAPO study ("Surviving ARDS: the influence of quality of care and
individual patient characteristics on quality of life") is to investigate the role of
quality of care and individual patient characteristics on quality of life and return to work
in survivors of ARDS (acute respiratory distress syndrome). It is hypothesized that higher
quality of care is associated with better health-related quality of life and a higher rate
of return to work among survivors.
A prospective, observational, multi-centre patient cohort study is performed in Germany,
using hospitals from the "ARDS Network Germany" as the main recruiting centres. It is
envisaged to recruit 2400 patients into the DACAPO study and to analyze a study population
of 1500 survivors. They will be followed up until 12 months after discharge from hospital.
Quality of care will be assessed as process quality, structural quality and volume at the
institutional level. The main outcomes (health related quality of life and return to work)
will be gathered by self-report questionnaires. Further data assessment includes general
medical and ARDS-related characteristics of patients as well as sociodemographic and
psycho-social parameters. Multilevel hierarchical modelling will be performed to analyse the
effects of quality of care and individual patient characteristics on outcomes, taking the
cluster structure of the data into account.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | May 2017 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - ARDS according to the criteria of the Berlin-Definition: i) Acute onset within one week, ii) bilateral pulmonary infiltrates (chest imaging), iii) respiratory failure not fully explained by cardiac failure or fluid overload. - informed consent provided by the patient or the legal guardian - 18 years old or older Exclusion Criteria: - no ARDS - no informed consent provided by the patient or the legal guardian - younger than 18 years |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Germany | Universitätsmedizin Charite | Berlin | |
Germany | Universitätsmedizin Göttingen | Göttingen | |
Germany | Klinik für Intensivmedizin | Hamburg |
Lead Sponsor | Collaborator |
---|---|
University Hospital Regensburg | University of Regensburg |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Health-related quality of life, measured by the Short-Form 12-item Health-Survey (SF-12) | change from baseline (discharge from the ICU) to 3 months, 6 months and 12 months, respectively. | 3 months, 6 months, 12 months after discharge from the ICU | No |
Secondary | return to work | Assessment by questionnaire | 3 months, 6 months, 12 months after discharge from the ICU | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03909854 -
Pragmatic Investigation of Volume Targeted Ventilation-1
|
N/A | |
Completed |
NCT02288949 -
Stratification of the Acute Respiratory Distress Syndrome
|
||
Recruiting |
NCT02574169 -
Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation
|
N/A | |
Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
Completed |
NCT05024500 -
Clinical and Functional Outcomes of Critically Ill Patients With COVID-19
|
N/A | |
Terminated |
NCT04511650 -
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
|
Phase 2 | |
Recruiting |
NCT01339533 -
Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation
|
Phase 2 | |
Active, not recruiting |
NCT01274260 -
Trial of Steroids in Pediatric Acute Lung Injury/ARDS
|
Phase 2 | |
Recruiting |
NCT03296059 -
Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates
|
N/A | |
Terminated |
NCT04609865 -
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
|
Phase 3 | |
Active, not recruiting |
NCT04009330 -
Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
|
||
Not yet recruiting |
NCT05847517 -
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
|
Phase 3 | |
Not yet recruiting |
NCT06127381 -
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
|
Phase 1 | |
Completed |
NCT01854424 -
Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS
|
N/A | |
Completed |
NCT03870009 -
Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS
|
N/A | |
Completed |
NCT04311697 -
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
|
Phase 2/Phase 3 | |
Recruiting |
NCT02095444 -
Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT04460859 -
RecruitmEnt Assessed by eleCtRical Impedance Tomography
|
||
Completed |
NCT01926093 -
Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients
|
N/A | |
Terminated |
NCT01506401 -
The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
|
Phase 3 |